Clinical trials: Vancomycin Resistance
Multidrug Resistant Organisms, Healthcare Associated Infections
Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)
Enhanced terminal room disinfection is a novel, promising, but still unproven strategy for the prevention of healthcare-associated infections (HAIs) due to selected multidrug-resistant (MDR) bacterial pathogens.
- Trial name
- NCT01579370
- Testing
- Quaternary ammonium, Bleach, Quaternary ammonium and UV-C light
- Where
- 9 sites in United States
- Volunteers
- 21,395 people
- Sponsor
- Duke University
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Methicillin-resistant Staphylococcus Aureus, Sepsis
Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project
Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Sepsis, Critical Illness
- Trial name
- NCT02945241
- Testing
- Vancomycin, Cystatin C dosing algorithm, Creatine clearance dosing algorithm
- Volunteers
- 399 people
- Sponsor
- Mayo Clinic
Clostridioides Difficile Infection
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
The goal of this clinical trial is to test whether lyophilized fecal microbime transfer - a dried extract of bacteria from the stool of healthy donors - is better than antibiotic therapy only for treating primary clostridioides…
- Trial name
- DONATE (NCT05709184)
- Testing
- Lyophilized fecal microbiome transfer, Vancomycin
- Where
- 6 sites in Canada, Hungary and 4 more
- Volunteers
- 196 people
- Sponsor
- Rambam Health Care Campus
Clostridium Difficile Infection
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
Vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant Enterobacteriaceae (CRE) are multi-drug resistant organisms (MDROs) associated with healthcare settings and are a high priority for containment in public health.
- Trial name
- NCT03643887
- Testing
- FMT Capsule DE
- Sponsor
- University of Wisconsin, Madison
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with acute bacterial skin and soft tissue infections.
- Trial name
- NCT01984684
- Testing
- delafloxacin, vancomycin, aztreonam
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Melinta Therapeutics, Inc.
Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized…
- Trial name
- VITORA (NCT03944369)
- Testing
- KB109, No intervention
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Kaleido Biosciences
Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
This study will evaluate the safety and effectiveness of daptomycin, an antibiotic compared to another one which is vancomycin when given around the time of joint replacement surgery.
- Trial name
- NCT01196169
- Testing
- Daptomycin, Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mountain Home Research & Education Corporation
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis
The purpose of this study is to determine the pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis.
- Trial name
- NCT01509339
- Testing
- Vancomycin
- Where
- United States
- Sponsor
- Case Western Reserve University
Endocarditis, Bacterial, Infective Endocarditis
Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
The overall goals of this study are to compare the safety and efficacy of daptomycin monotherapy 10 mg/kg/day and vancomycin monotherapy dosed to achieve vancomycin trough levels of 15 to 20 μg/mL for the treatment of…
- Trial name
- HDSAB (NCT00695903)
- Testing
- daptomycin, vancomycin
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Anti-biotic Resistance
A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE
The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, VSL#3 versus oral placebo for reducing colonization by VRE.
- Trial name
- PROVE (NCT00933556)
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Wisconsin, Madison
Antimicrobial Resistance, Colonization
Fecal Microbiota Transplantation for CRE/VRE
Multidrug-resistant organisms (MDRO) present an increasingly serious public health threat to the global community.The prevalence of various MDRO, including carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant…
- Trial name
- NCT03479710
- Testing
- FMT infusion
- Where
- Hong Kong
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
VRE Colonization
Probiotic Efficacy in VRE Eradication
This study will evaluate the efficacy of a probiotic lactobacillus strain in eradicating VRE in non-symptomatic carriers after 4 weeks of treatment. It will also evaluate the long-term efficacy after 8,16 and 24 weeks.
- Trial name
- PROVE (NCT03560700)
- Testing
- lactobacillus probiotic strain
- Where
- Denmark
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Infection
Reduction of Nosocomial Vancomycin -Resistant Enterococci (VRE) Colonization and Infection by Active Surveillance and Intervention of Infection Control
Vancomycin -resistant enterococci(VRE) has emerged as one of the most common nosocomial pathogen of health-care associated infection since 1988.
- Trial name
- NCT01201031
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Medical University WanFang Hospital
VRE Infection, Antibiotic Resistant Infection
Assessing the Impact of Antimicrobial Exposure and Infection Control Measures on the Spread of VRE
The AEGON study is a German multicenter, prospective observational study. The study consists of two parts, which are carried out at all participating study sites and include two different patient cohorts.
- Trial name
- AEGON (NCT04624464)
- Testing
- Rectal swabs - microbiological analysis, Examination of patient room
- Where
- Germany
- Volunteers
- 170 people
- Sponsor
- University Hospital of Cologne
Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference…
- Trial name
- NCT01561469
- Testing
- Linezolid, Vancomycin
- Volunteers
- 188 people
- Sponsor
- Pfizer
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Vancomycin Resistant Enterococci Infection, Clostridium Difficile Infection
Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial
With the construction of a new medical teaching ward with features designed to reduce hospital-acquired infections, we hypothesized that the design of the new ward was the major factor that contributed to the improved outcomes…
- Conditions
- Vancomycin Resistant Enterococci Infection, Clostridium Difficile Infection, Nosocomial Infection, Methicillin Resistant Staphylococcus Aureus Infection (MRSA)
- Trial name
- NCT00563186
- Testing
- Admission to a novel hospital ward
- Where
- Canada
- Volunteers
- 1,514 people
- Sponsor
- University of Calgary
Skin Diseases, Infection
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects
The main purpose of this study is to compare the safety and efficacy of tigecycline versus clindamycin (including subjects treated with vancomycin) in pediatric subjects (aged 8 to 17 years) with complicated skin and skin…
- Trial name
- NCT00911573
- Testing
- Tigecycline, Clindamycin (or Vancomycin if needed)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumonia, Ventilator-Associated
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours.
- Trial name
- NCT00572559
- Testing
- Vancomycin, Linezolid
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- Pfizer